Huakang Biomedical Holdings Company Limited, an investment holding company incorporated in the Cayman Islands in 1992 and headquartered in Tsim Sha Tsui, Hong Kong, with principal operations in the People's Republic of China, engages in the research, development, production, marketing and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment; as well as healthcare products and supplements. The company offers a portfolio of 31 biological reagents, including 28 male fertility in-vitro diagnostic reagents, two parasite antibody detection reagents and one Epstein-Barr virus antibody detection reagent; auxiliary reproductive supplies and equipment such as semen biochemical immunoassay equipment; and healthcare supplements previously marketed under the Nutronic brand. It sells products directly to hospitals and medical institutions, as well as through distributors, primarily serving the healthcare sector in the PRC with a focus on male infertility diagnostics and assisted reproductive technologies. In April 2025, an indirect wholly-owned subsidiary entered into an equity transfer agreement to acquire 91% of Hunan Keyue Biotechnology Co., Ltd., a PRC-based entity specializing in women's health products including female reproductive solutions, health foods and antibacterial items under the Yukunshu and Qinghuiyue brands, for RMB317,697, marking a strategic expansion into the women's health market; the company also completed placings of 82 million shares in early 2024 raising approximately HK$8 million and registered its semen biochemical immunoassay equipment as a Class II medical device in late 2024, while suspending Nutronic sales amid market challenges.